Applied Dna Sciences Inc (BNBX)

$BNBX 29 trading days under $1. Does someone have contact with IR and can ask what happens if they're under 1 for 30 days since APDN used up all its reverse stock splits? Or does BNBX start from zero?

BNB Plus Corp. (Nasdaq: $BNBX) announced today that its biopharmaceutical subsidiary, LineaRx, Inc., has been granted a European patent by the European Patent Office (EPO) covering the composition of LineaRx’s chemically modified RNA polymerase enzyme, branded Linea RNAP. The patent, entitled “Compositions and Methods for RNA Synthesis” (EP4232569A1), follows a U.S. patent grant in 2024. The company plans to validate the patent in key European markets, with protection expected to extend through at least 2040. BNB Plus Corp. (Nasdaq: BNBX) is a B2i Digital Featured Company. See the comprehensive profile at https://b2idigital.com/bnbx. The European grant is intended to extend LineaRx’s intellectual property protection to key European markets. Linea RNAP is a core component of the Linea IVT (in vitro transcription) platform, which the company believes enables mRNA manufacturers to produce better mRNA faster through a simplified workflow with reduced double-stranded RNA (dsRNA) contamination. The technology was acquired through BNBX’s purchase of Spindle Bio, Inc. in July 2023. “Securing patent protection in Europe is a significant milestone in building our global intellectual property portfolio around Linea IVT,” said Clay Shorrock, CEO of BNBX. “Together with our U.S. patent, this European grant strengthens LineaRx’s position to help mRNA manufacturers produce higher-quality mRNA more efficiently and supports potential monetization of the Company’s intellectual property in the rapidly growing European biotherapeutics market.” Read the full press release: https://www.businesswire.com/news/home/20260318656669/en/ The Linea IVT platform combines DNA IVT templates manufactured via the Linea DNA platform with the proprietary Linea RNAP to enable mRNA and sa-mRNA manufacturers to produce better mRNA faster. Advantages over conventional production include the elimination of plasmid DNA as a starting material, the prevention or reduction of dsRNA contamination, and simplified production workflows. BNB Plus Corp. is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman, CFA as Chief Investment Officer; Josh Kruger, as Chairman of the Board; and JR Pasch, as Strategic Advisor. To learn more about BNB Plus Corp., visit www.BNB.plus. For investor inquiries, contact [email protected]. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

$BNBX Down 40% since the start of the year and zero insider buys. But lots of marketing about how great the opportunity is.

$BNBX Gnarly but looking for a big reversal

$BNBX I wonder if the atm is keeping it down.

$BNBX Current Stock Price: $0.73

$BNBX P&D nothing more

$BNBX where the fuck is the money going

$BNBX rs spilt here wouldn’t even make sense when you have 5.5 million shares lol isn’t that funny